Navigation Links
Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009
Date:8/6/2009

---------------- EXPENSES License and royalty fees 2,568 - 2,568 Cost of products sold 25,682 (896) b 24,786 Research and development 6,833 (739) c 6,094 Selling, general and administrative 21,606 (2,548) d 19,058 Depreciation and amortization 8,296 (7,453) e 843 --------------------------------- --------------------------------------- 64,985 (11,636) 53,349 --------------------------------- --------------------------------------- Operating (loss) income (412) 11,238 10,826 --------------------------------- --------------------------------------- Other income (expenses): Foreign exchange (loss) gain (1,441) 1,441 f - Investment and other income (loss) (600) 636 g 36 Loss on sale/write-down of investments - - - Interest expense on long-term debt (9,641) 750 i (8,891) --------------------------------- --------------------------------------- --------------------------------- --------------------------------------- (11,682) 2,827 (8,855) --------------------------------- --------------------------------------- --------------------------------- --------------------------------------- (Loss) income before income taxes (12,094) 14,065 1,971 Income tax (recovery) expense (217) 3,960 j 3,743 --------------------------------- --------------------------------------- --------------------------------- --------------------------------------- Net loss for the period (11,877) 10,105 (1,772) --------
'/>"/>
SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

Related biology technology :

1. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
2. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
3. Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation
4. Angiotech to participate in UBS Global Life Sciences Conference
5. Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial
6. Angiotech Receives CE Mark Approval of Quill(TM) SRS MONODERM(TM), a New Rapidly Resorbing Suture Product Line
7. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
8. Angiotech to participate in Bank of America 2007 Credit Conference
9. Angiotech to participate in RBC 2007 Healthcare Conference
10. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
11. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 2014  Pfenex Inc. (NYSE MKT: PFNX), a ... high-value and difficult to manufacture proteins including biosimilar ... financial results for the second quarter ended June ... of our initial public offering, we have the ... candidates, derived from our proprietary protein expression platform," ...
(Date:8/29/2014)... Pittcon is pleased to announce that the 2015 ... Scientific, have organized a session on nanotechnology for presentation ... Asia’s largest analytical and scientific instruments show, will be ... , The four speakers in this U.S. symposium, “Thinking ... Single Cells” will present their use of nanotechnology to ...
(Date:8/29/2014)... Due to a misstatement posted by the ... Cell Technology Center, LLC ( ASCTC ) was reported as ... that might benefit ALS patients. Because of ASCTC's exclusive ... technologies and therapeutic applications, FRC listed ASCTC as one of ... who wish not to support research that requires the death ...
(Date:8/28/2014)... August 28, 2014 Best Sanitizers, Inc., ... the food processing industry, is asking industry professionals to ... comparison of the E2 soap they’re currently using to ... Soap . Hand hygiene is critical to fighting ... processing environment. Six key criteria are identified to evaluate ...
Breaking Biology Technology:Pfenex Reports Second Quarter 2014 Results and Provides Business Update 2Pfenex Reports Second Quarter 2014 Results and Provides Business Update 3Pfenex Reports Second Quarter 2014 Results and Provides Business Update 4Pfenex Reports Second Quarter 2014 Results and Provides Business Update 5Pfenex Reports Second Quarter 2014 Results and Provides Business Update 6Pfenex Reports Second Quarter 2014 Results and Provides Business Update 7Pfenex Reports Second Quarter 2014 Results and Provides Business Update 8Fifth Annual U.S. Symposium at JASIS Organized by Pittcon’s Program Chairman Hub MacDonald 2The Adult Stem Cell Technology Center, LLC Declines ALS Ice Bucket Challenge Donors Wishing to Support Ethical Research for New Stem Cell Therapies 2The Adult Stem Cell Technology Center, LLC Declines ALS Ice Bucket Challenge Donors Wishing to Support Ethical Research for New Stem Cell Therapies 3Best Sanitizers, Inc. Asks Food Industry Professionals: With Fall Harvest On the Way, Is Your E2 Hand Soap Up to the Task? 2
... funded by Cadila Pharmaceuticals and Revenues from Sales ... in Novavax , ROCKVILLE, Md., March 31 ... today it has formed a joint venture with ... and market vaccines, pharmaceuticals and diagnostic products in ...
... more to attend global event for health care leaders in ... , D.C. ... Congress, April 14-16, Washington, D.C., is pleased to announce several ... with top health leaders from the United States and colleagues ...
... Calif., March 31 Based on its recent ... & Sullivan recognizes Carl Zeiss Meditec with the ... Award for its optical coherence tomography (OCT) technology ... pioneer of OCT technology and has launched clinical ...
Cached Biology Technology:Novavax Announces New Capital Infusion Through a Strategic Alliance with Cadila Pharmaceuticals of India 2Novavax Announces New Capital Infusion Through a Strategic Alliance with Cadila Pharmaceuticals of India 3Novavax Announces New Capital Infusion Through a Strategic Alliance with Cadila Pharmaceuticals of India 4Novavax Announces New Capital Infusion Through a Strategic Alliance with Cadila Pharmaceuticals of India 5Novavax Announces New Capital Infusion Through a Strategic Alliance with Cadila Pharmaceuticals of India 6Health Care Innovations and Opportunities Attract Attendees from 40 Countries and Delegations from 12 to 6th Annual World Health Care Congress 2Frost & Sullivan Lauds Carl Zeiss Meditec for Dominating the OCT Market for Ophthalmic Applications 2Frost & Sullivan Lauds Carl Zeiss Meditec for Dominating the OCT Market for Ophthalmic Applications 3Frost & Sullivan Lauds Carl Zeiss Meditec for Dominating the OCT Market for Ophthalmic Applications 4
(Date:8/29/2014)... UC Davis have made some surprising discoveries about ... simian immunodeficiency virus (SIV), the team found that ... are early responders to viral invasion and are ... cytokine called interleukin-1 beta (IL-1β). , Though ... breakdown of the gut epithelium that provides a ...
(Date:8/29/2014)... has been known about what genetic changes transform wild ... one of whom is a University of Montana assistant ... controlling the development of the brain and the nervous ... was published Aug. 28 in Science and ... at http://www.sciencemag.org/ ., The domestication of animals and ...
(Date:8/29/2014)... understand how the repeated climatic shifts over the ... of genetic diversity, a team of researchers led ... Ana Carnaval developed a new biodiversity metric called ... which the genetic variation within species is restricted ... professor of biology, and 14 other researchers from ...
Breaking Biology News(10 mins):The early cost of HIV 2New research reveals how wild rabbits were genetically transformed into tame rabbits 2New research reveals how wild rabbits were genetically transformed into tame rabbits 3CCNY team defines new biodiversity metric 2
... that it is launching a new journal, the Journal ... be published bimonthly, and will focus on the advances ... and engineering. The first issue will appear in late ... Engineering will cover the fields of natural gas exploration, ...
... Johns Hopkins and Ohio State University have found that the ... severity of colon cancer in a mouse model. Publishing in ... how trisomy 21, or Down syndrome in humans, can repress ... 50-year-old debate about whether people with Down syndrome develop cancer ...
... you really are is a fairly harmless, socially accepted habit ... matter of life and death for caterpillars of large blue ... one of the ants own larvae. In a publication in ... for Social Evolution (CSE) at the University of Copenhagen show ...
Cached Biology News:Elsevier launches new journal: Journal of Natural Gas Science and Engineering 2Gene dose affects tumor growth 2Smell-wars between butterflies and ants 2
anti-JNK2 Immunogen: Recombinant human JNK2 protein Accession Number: NM_002752 Quality Assurance: Routinely evaluated by immunoblot. Molecular Weight: 46 and/or 54 kDa Available ...
... Synthetic peptide derived from the internal region ... Specific for the internal region of ... identifies the target band at ~590 kDa. ... secreted media from primary tracheobranchial epithelial cultures ...
Gloves are 9.25 long, latex, powder free, smooth and ambidextrous....
Lipid-rich bovine serum albumin for cell culture. It is chromatographically purified and has an IgG content 1.0% (w/w)....
Biology Products: